A recent study has found that glucagon-like peptide 1 receptor agonists (GLP-1 RAs), commonly used for treating diabetes or obesity, are linked to lower quality bowel preparation for colonoscopies and an increased need for repeat procedures. This research was conducted by a team led by Dr. Eric J. Vargas from the Mayo Clinic in Rochester, Minnesota, and published in the American Journal of Gastroenterology. Key Findings: The findings are significant as GLP-1 RAs are increasingly used for diabetes and obesity treatment. They are known to reduce gastrointestinal motility, which may contribute to suboptimal bowel preparation. This study underscores the importance…
Author: Abhay Panchal
A collaborative study involving Brigham and Women’s Hospital, Massachusetts Institute of Technology, Celero Systems, and West Virginia University has tested a new wireless ingestible device for monitoring vital signs. The device, known as the Vitals Monitoring Pill (VM Pill), has shown promise in a pilot clinical study involving 10 people with sleep apnea and in a preclinical model for opioid-induced respiratory depression. Key aspects of the study and the VM Pill include: This study represents a significant step in the development of non-invasive, efficient health monitoring technologies, with potential broad applications in healthcare.
The American Academy of Pediatrics (AAP) has released new guidance for pediatricians regarding the use of fecal microbiota transplantation (FMT) in children. This guidance is detailed in a clinical report titled “Guidance for the Clinician in Rendering Patient Care Fecal Microbiota Transplantation: Information for the Pediatrician,” published in the December 2023 issue of Pediatrics. Key points from the AAP’s guidance include: The AAP’s clinical report supports the joint society statement by the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology and Nutrition.
The American Gastroenterological Association (AGA) has released a new guideline, published in Gastroenterology, recommending the use of blood and stool-based biomarkers for managing Crohn’s disease. This guideline marks a significant advancement in the non-invasive monitoring of this condition. Key points from the guideline include: The guideline underscores that biomarkers are no longer experimental and should be an integral part of IBD care. They offer a less invasive, more cost-effective alternative to frequent colonoscopies and allow for more frequent assessments for tighter disease control and better long-term outcomes in Crohn’s disease patients.
UnitedHealthcare (UHC) is facing a class action lawsuit for allegedly using an artificial intelligence (AI) system, nH Predict, to deny patient claims in Medicare Advantage plans. The lawsuit, filed in Minnesota district court, claims UHC used this technology to systematically reject skilled nursing facility (SNF) claims, contradicting Medicare’s coverage standards and doctor recommendations. The AI model, acquired by UHC’s parent company in 2020, is accused of having a 90% error rate, leading to significant out-of-pocket expenses for patients. The lawsuit highlights two cases: Gene Lokken, who incurred about $150,000 in expenses, and Dale Tetzloff, who paid around $70,000. Both patients…
A study published in JAMA Network Open, finds that conventional colonoscopy remains the most cost-effective method for universal colorectal cancer (CRC) screening in average-risk adults in the US, compared to circulating tumor DNA-based methods (liquid biopsy). Key points from the study include: The study underscores the current economic advantage of colonoscopy for CRC screening while acknowledging the potential future role of liquid biopsy as technology advances.
Universal DX (UDX), a liquid biopsy firm, successfully closes a Series B financing round of approximately $70 million. Key highlights from the article include: The article underscores the significant progress in developing non-invasive, efficient methods for colorectal cancer screening, which could potentially transform cancer detection and management.
Researchers at UMass Lowell’s Zuckerberg College of Health Sciences are investigating the connection between the gut microbiome and the risk of Parkinson’s and Alzheimer’s diseases. This research could lead to earlier detection and novel treatments for these neurodegenerative diseases, which affect millions globally. Key findings and initiatives from the study include: Link Between Gut Microbiome and Parkinson’s Disease: The study, led by Associate Professor Natalia Palacios, found that healthy, anti-inflammatory bacteria were less abundant in individuals diagnosed with Parkinson’s disease. This suggests a potential link between gut inflammation and Parkinson’s, with changes in the gut microbiome observable before the disease’s…
Claris GenomiX, a precision oncology company, has announced the licensing availability of ColoType, its patented mRNA-based Consensus Molecular Subtyping (CMS) assay. This diagnostic tool is designed to guide treatment decisions for colorectal cancer (CRC). Key highlights from the announcement include:
Biotech company AnchorDx has formed a long-term partnership with molecular diagnostics firm DiaCarta to develop and commercialize cancer diagnostic products globally. Based in Guangzhou, China, AnchorDx, and Pleasanton, California-based DiaCarta plan to leverage their proprietary technologies for DNA methylation and mutation detection in this collaboration. The financial and other terms of the partnership were not disclosed. AnchorDx aims to accelerate its early cancer screening programs and develop a robust product pipeline through this collaboration. The company’s pipeline currently covers over 70% of high-incidence cancers. AnchorDx received breakthrough device designation from the U.S. Food and Drug Administration in 2021 for its…